Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. exitaplasia

ExitAplasia

Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ExitAplasia project word cloud

Explore the words cloud of the ExitAplasia project. It provides you a very rough idea of what is the project "ExitAplasia" about.

broaden    marking    treatment    toxicological    severe    stakeholder    risk    least    aggressive    healthcare    explore    causes    morbidity    length    with    regstem    leukaemia    pain    injection    day    found    25    days    turnover    room    million    networks    innovation    infection    10    validation    21    destruction    game    global    reformulate    substantially    dying    changing    2023    99    off    feasibility    pasteur    world    clinical    deaths    jobs    company    fragile    regeneration    aplasia    acute    tremendous    opportunity    start    improvement    70    triggers    situation    french    accelerating    famous    x310    recovery    cancer    awarded    hospital    2027    health    deficient    innovative    decrease    commercialisation    exit    sterile    patient    market    shortening    spin    medicine    stay    ce    death    costing    faster    red    difficult    blood    share    chemotherapy    portion    immunity    7    patients    intravenous    actual    solution    disrupt    14    speeds    points    paris    founded    complete    acquired    cells    business    breakthrough    reg    extremely    speed    relation    exitaplasia    white   

Project "ExitAplasia" data sheet

The following table provides information about the project.

Coordinator		 REGSTEM 

Organization address
address: 24 RUE DU FAUBOURG SAINT-JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website https://www.regstem.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGSTEM FR (PARIS) coordinator 50˙000.00

Map

 Project objective

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXITAPLASIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXITAPLASIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

PICSOHF (2020)

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Read More